Current status on microRNAs as biomarkers for ovarian cancer
Research output: Contribution to journal › Review › Research › peer-review
Standard
Current status on microRNAs as biomarkers for ovarian cancer. / Prahm, Kira Philipsen; Novotny, Guy Wayne; Høgdall, Claus; Høgdall, Estrid.
In: APMIS - Journal of Pathology, Microbiology and Immunology, Vol. 124, No. 5, 05.2016, p. 337-55.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Current status on microRNAs as biomarkers for ovarian cancer
AU - Prahm, Kira Philipsen
AU - Novotny, Guy Wayne
AU - Høgdall, Claus
AU - Høgdall, Estrid
N1 - © 2016 APMIS. Published by John Wiley & Sons Ltd.
PY - 2016/5
Y1 - 2016/5
N2 - Ovarian cancer (OC) is the most lethal gynecological malignancy in the Western world, and has a very poor prognosis, often due to late diagnosis and emergence of chemotherapy resistance. Therefore, there is an essential need for new diagnostic and prognostic markers that can improve and initiate more personalized treatment, eventually improving survival of the patients. MicroRNAs are small, non-coding RNA molecules, that post-transcriptionally regulate gene expression. Several studies have within the last decade shown that microRNAs are deregulated in OC and have potential as diagnostic and prognostic biomarkers for OC. Recently studies have also focused on microRNAs as predictors of chemotherapy responses and their potential as therapeutic targets. However, many of the published studies are difficult to interpret as a whole due to various methods of analysis. Future focus should be aimed at developing a general standardized analytical method, which can limit differences between studies thus allowing easier comparison across them. In addition, validation of studies in independent series that ideally should be histotype-specific is essential to determine the clinical role of microRNAs in different types of OC. In this review we summarize the current knowledge of microRNAs as potential biomarkers for OC, with focus on their clinical relevance.
AB - Ovarian cancer (OC) is the most lethal gynecological malignancy in the Western world, and has a very poor prognosis, often due to late diagnosis and emergence of chemotherapy resistance. Therefore, there is an essential need for new diagnostic and prognostic markers that can improve and initiate more personalized treatment, eventually improving survival of the patients. MicroRNAs are small, non-coding RNA molecules, that post-transcriptionally regulate gene expression. Several studies have within the last decade shown that microRNAs are deregulated in OC and have potential as diagnostic and prognostic biomarkers for OC. Recently studies have also focused on microRNAs as predictors of chemotherapy responses and their potential as therapeutic targets. However, many of the published studies are difficult to interpret as a whole due to various methods of analysis. Future focus should be aimed at developing a general standardized analytical method, which can limit differences between studies thus allowing easier comparison across them. In addition, validation of studies in independent series that ideally should be histotype-specific is essential to determine the clinical role of microRNAs in different types of OC. In this review we summarize the current knowledge of microRNAs as potential biomarkers for OC, with focus on their clinical relevance.
KW - Biomarkers, Tumor
KW - Female
KW - Humans
KW - MicroRNAs
KW - Ovarian Neoplasms
KW - Prognosis
U2 - 10.1111/apm.12514
DO - 10.1111/apm.12514
M3 - Review
C2 - 26809719
VL - 124
SP - 337
EP - 355
JO - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica
JF - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica
SN - 0903-4641
IS - 5
ER -
ID: 173940030